This study was designed to compare the effectiveness of fluconazole vs. itraconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. HIV-infected patients who had been successfully treated (achieved negative culture of CSF) for a first episode of cryptococcal meningitis were randomized to receive fluconazole or itraconazole, both at 200 mg/d, for 12 months. The study was stopped prematurely on the recommendation of an independent Data Safety and Monitoring Board. At the time, 13 (23%) of 57 itraconazole recipients had experienced culture-positive relapse, compared with 2 relapses (4%) noted among 51 fluconazole recipients (P Å .006). The factor best associated with relapse was the patient having not received flucytosine during the initial 2 weeks of primary treatment for cryptococcal disease (relative risk Å 5.88; 95% confidence interval, 1.27 -27.14; P Å .04). Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease. Flucytosine may contribute to the prevention of relapse if used during the first 2 weeks of primary therapy.
Cryptococcal meningitis occurs in 3% -10% of patients with with AIDS. In a large comparative trial of daily oral fluconazole therapy (200 mg/d) vs. weekly intravenous amphotericin B HIV-1 disease [1] . Primary treatment of acute disease consists of high-dose amphotericin B, with or without flucytosine (5-(1.0 mg/[kgrwk] ), recurrent disease occurred in 3% of fluconazole recipients vs. 22% of those receiving amphotericin B fluorocytosine, 5-FC), for 2 weeks followed by 8 weeks of oral fluconazole (400 mg/d) [2, 3] . Other treatment modalities exist over 1 year [8] . Toxicity was more common in the amphotericin B group, with 15% of patients requiring discontinuation of as well, including use of liposomal amphotericin B and combination therapy with fluconazole and flucytosine [4 -6] . Even therapy because of serious adverse events compared with 5% of fluconazole recipients. after successful therapy, defined as achievement of negative CSF culture by week 10, relapse of cryptococcal meningeal disease occurs in 25% -60% of patients unless long-term mainSee editorial response by Larsen on pages 297 -8. tenance therapy is used [7, 8] .
Oral fluconazole has been established as the treatment of The most common side effects associated with fluconazole choice to prevent relapse of cryptococcal disease in patients consisted of gastrointestinal symptoms (nausea, vomiting) in 22% of patients, skin rashes in 13%, and moderate hepatotoxicity in 11%. The side effects that led to discontinuation of fluconazole included skin rash in three patients, abnormal liver coccal disease (reviewed in [9] ). In three pilot studies of itracoPharmacologic assays. Fluconazole blood levels were determined by using a gas-liquid chromatography technique [13] nazole, 18 (64%) of 36, 11 (38%) of 29, and 5 (42%) of 12 of HIV-infected patients with cryptococcal meningitis were and itraconazole levels were assayed by HPLC [14] in the laboratory of Dr. Michael Rinaldi (University of Texas Health successfully treated [10 -12] ; these data are comparable to success rates observed with fluconazole therapy [3] . The role of Sciences Center, San Antonio). Serum samples were collected at each study visit, stored at 020ЊC, and shipped to the central itraconazole as maintenance therapy for patients with HIVassociated cryptococcal disease has not been evaluated. To laboratory for analysis. CSF concentrations of study drugs were not determined. address this question, a phase III comparative trial of itraconazole vs. fluconazole was initiated, and the results of this study Statistical considerations. The objective of this study was to show equivalence between fluconazole and itraconazole. The are presented herein.
hypothesis, which we hoped to reject, was that the relapse rate in the itraconazole group would be at least 15% greater than Methods the relapse rate in the fluconazole group (expected to be £10%). The ability to detect a 15% difference with a oneStudy design. A randomized, double-blind, controlled clinical trial of fluconazole vs. itraconazole as maintenance therapy sided test a Å .025 (two-sided equivalence, .05) and b Å .20 (power of 80%) required 65 patients per group [15] . was done in HIV-infected patients who had been successfully managed with primary therapy for an acute episode of cryptoAn intent-to-treat analysis of all patients meeting eligibility criteria is presented. Comparability of the treatment regimens coccal meningitis. Patients were enrolled at 24 study sites throughout the United States. A listing of participating instituwas determined by x 2 analysis (two-tailed) for categorical factors and the Kruskal-Wallis two-sample test for continuous tions is provided after the text. Patients were eligible for enrollment if they were HIV-infected; were §13 years of age; had factors [16] . A Kaplan-Meier survival analysis with log-rank test was used to compare the two therapies for time to relapse been successfully treated for acute cryptococcal meningitis, as judged by a negative CSF culture within the 2 weeks before (culture and/or clinical) [17] . Cox's proportional hazards model was used to assess the effect of potentially confounding varienrollment, and had no clinical evidence of disease; had received at least 6 weeks of therapy for acute disease with either ables on the risk of relapse [18] . Factors assessed for their association with a positive CSF culture relapse included age, amphotericin B (with or without flucytosine), fluconazole, or itraconazole (use of intrathecal amphotericin B was not alrace (white/nonwhite), sex, AIDS risk group (homosexual/bisexual vs. other), all pretreatment CSF laboratory values, hislowed); were not receiving histamine 2 blockers, antacids, rifampin, rifabutin, phenytoin, or phenobarbitol; had acceptable tory of Pneumocystis carinii pneumonia, serum cryptococcal antigen group, maintenance therapy (fluconazole vs. itraconahematologic, metabolic, hepatic, and renal laboratory parameters; and agreed to participate and signed an informed consent zole), and acute therapy using flucytosine. Factors with a univariate P value of £.30 initially included in the multivariate document.
Once entered into the trial, the study participants were ranmodel were sex, risk group, serum antigen, acute therapy with flucytosine, and maintenance therapy. domly assigned to receive, in a blinded fashion, either fluconazole (200 mg/d) or itraconazole (200 mg/d), both administered Interim analysis was scheduled at the time that 50% of participants had entered the study to ensure that there was no obviorally with food, orange juice, or a cola drink, and followed up for 12 months. Randomization was stratified by study site ous benefit to one of the treatment regimens and to examine overall treatment safety and trial conduct. The O'Brienand prior therapy for the acute episode. Clinical and laboratory safety evaluations were done at study entry, every 2 weeks for Fleming stopping boundaries were used to determine whether one treatment arm was significantly superior to the other [19] the first 3 months, and every 4 weeks thereafter. CSF was obtained at baseline, at the end of the study, and at any time a while maintaining an overall significance level of 5%. The National Institute of Allergy and Infectious Diseases MSG Data patient presented with signs or symptoms suggestive of clinical relapse of cryptococcal disease.
Safety and Monitoring Board (DSMB) served as interim reviewers of the conduct of this study. The primary end point of the study was successful outcome, defined as no evident disease at the last study visit. Unsuccessful outcome was defined as culture-positive (CSF or serum) Results relapse with no clinical disease, clinical evidence of relapse with a CSF culture positive for C. neoformans, clinical eviOver the 27 months of the study, 118 patients were enrolled, 10 of whom were ineligible because of a CSF culture positive dence of cryptococcal meningitis with no culture obtained (confirmed by a blinded review panel of the Mycoses Study Group for C. neoformans at baseline (5 assigned to each treatment group). Among the remaining 108 evaluable patients, 57 as- [MSG] ), or death due to cryptococcal disease. Autopsies were not routinely done on study patients. Participants who died of signed to itraconazole and 51 to fluconazole, no differences in baseline demographics were noted between the two treatment other causes were included in the overall survival analysis but were not included as an unsuccessful outcome if the patients groups (table 1) . Primary therapy for the acute episode of cryptococcal meningitis prior to entry into this study was similar had no evidence of cryptococcal disease at their last visit.
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01-20-99 06:55:01 cidal UC: CID between the fluconazole and itraconazole groups, with the maAt the planned interim analysis of the study, the DSMB concluded there was insufficient reason to close the study. jority of patients (79%) initially receiving amphotericin B, with or without flucytosine, followed by ''consolidation'' therapy However, the DSMB recommended that the study statistician should follow the number of relapses carefully and notify the with either itraconazole (37%) or fluconazole (40%). Primary monotherapy with fluconazole (17%) or itraconazole (4%) was DSMB should an inordinate number of new relapses occur. Four months later, an increasing number of relapses of cryptoused in 22 of the 108 evaluable patients, and 10 weeks of amphotericin B was used as initial therapy in 2 patients (2%).
coccal meningitis prompted a special meeting of the DSMB. The Board recommended that ''MSG study #25 be terminated The median baseline serum and CSF cryptococcal antigen titers were 1:512 and 1:32, respectively, with no significant differ-. . . based on the data available which indicates definitive superiority of one of the two treatment arms.'' The study was ence between the treatment groups. No differences between treatment groups were noted in median values for baseline CSF stopped after accruing 118 patients. At the time the DSMB stopped the trial, 13 (23%) of 57 glucose (median, 51 mg/dL), protein (46 mg/dL), WBC count (1 cell/mm 3 ), or opening pressure (185 mm H 2 O). The median itraconazole recipients had a CSF culture -positive relapse of cryptococcal disease, compared with 2 (4%) of 51 patients who CD4 cell count was 10/mm 3 in each treatment group. There was only one formal interim analysis planned on this had a CSF culture -positive relapse while receiving fluconazole (table 2; figure 1 ). All culture -positive relapses were symptomstudy. For a typical trial aimed at identifying treatment differences, a stopping boundary of 0.005 would be recommended atic. In addition to the culture-positive relapses, 2 additional patients, 1 in each treatment group, were judged by the blinded by the O'Brien-Fleming method. Being that this is an equivalence trial, direct extension of this stopping-rule to apply to MSG review panel to have experienced a clinical relapse of cryptococcal meningitis, although with negative CSF cultures. the case in which equivalence can be determined was not considered. However, the primary aim of the preliminary analysis
The differences between treatment groups for relapse estimates for both culture-positive and clinical relapses or culturewas to ensure that there was no obvious benefit to one of the treatment regimens and to examine overall treatment safety positive relapses only were 19% (95% CI, 8% -29%). On the basis of these data, the null hypothesis, which stated that flucoand trial conduct. Thus, for this equivalence trial, we concluded that an obvious benefit of a treatment would be determined if nazole would be at least 15% better than itraconazole, could not be rejected for clinical or culture relapse (P Å .712) or the O'Brien-Fleming boundary was crossed. The second boundary was violated.
culture-positive relapse only groups (P Å .735). Therefore, Chose to discontinue 5 (10) 3 (5) P Å .06]), respectively. However, the only significant factor Adverse experience 1 (2) 3 (5) Poor compliance 2 (4) 1 (2) associated with value for independent predictive relapse was
Abnormal laboratory results 0 1 (2) whether the patient received flucytosine during the initial 2
Lost to follow-up 2 (4) 1 weeks of primary treatment for acute cryptococcal disease, with an RR of 5.88 (95% CI, 1.27 -27.14; P Å .04) for those not ents and 54% of itraconazole recipients. Serum concentrations † Three more patients died after discontinuation of protocol therapy. None of the deaths were due to cryptococcal disease. of itraconazole were consistently lower than fluconazole concentrations, with mean concentrations of 0.644 mg/mL (range, 0.0 -9.3 mg/mL) for itraconazole recipients, compared with equivalence between the two treatment groups could not be established. None of the patients who relapsed died as a result of cryptococcal disease. Overall mortality was 13%, with deaths occurring in 8 (16%) of 51 fluconazole patients and 6 (10%) of 57 itraconazole patients (P Å .809).
In a univariate analysis to determine predisposing factors associated with the clinical likelihood of relapse, none of the following factors were associated statistically with relapse: age, race, sex, AIDS risk group, baseline serum or CSF cryptococcal antigen titer or any other CSF laboratory parameter, or consolidation therapy with itraconazole (all P values ú .05). The only factors associated with relapse of cryptococcal disease were the assigned maintenance treatment regimen, itraconazole vs. fluconazole (P Å .005), and no use of flucytosine during the initial 2 weeks of primary treatment (P Å .01). Treatment with other primary regimens, for example, amphotericin B followed by fluconazole or itraconazole for the remainder of the primary treatment period (consolidation therapy) or azole alone, did not influence the risk of later relapse while receiving maintenance therapy. Among the 15 patients who relapsed, 2 were initially treated with amphotericin B plus flucytosine and received itraconazole as consolidation therapy; 5 received amphotericin B alone and received fluconazole as consolidation therapy; 3 received amphotericin B alone followed by itraconazole as consolidation therapy; 4 received fluconazole only; and 1 received only itraconazole. Thus, 13% (2 of 15; 95% CI, 2% -40%) of relapsing patients vs. 48% (45 of 93; 95% CI, 37% -59%) of .38 mg/mL (range, 0 -22.57 mg/mL) for those receiving fluneed for intravenous access and the associated costs of hospitalization or intensive home-based therapy. conazole. However, within each treatment group, neither itraconazole nor fluconazole serum levels predicted failure of mainteSeveral factors may have contributed to the higher rate of relapse among itraconazole recipients. Itraconazole may be innance therapy.
The majority of patients in each treatment group (64% fluherently less active against C. neoformans than is fluconazole in vivo, although no significant differences are noted between conazole and 56% itraconazole) reported no side effects due to their assigned study drug. Adverse experiences for each drug the two agents in animal studies of cryptococcal meningitis or in in vitro studies of susceptibility [9] . Drug concentrations of were similar to those published previously. Four patients were discontinued from study drug because of toxicity: two patients itraconazole in plasma were uniformly lower than those achieved with fluconazole; this difference could not be exwith skin rash and one each with severe anemia and gastrointestinal toxicity. No unanticipated or life-threatening adverse plained by the use of concomitant medications that interfere with itraconazole absorption or increased drug metabolism. events were reported for either drug.
That fact, combined with the relatively low penetration of itraconazole into the CSF through the blood-brain barrier, indicates that pharmacologic factors may play a role in the decreased Discussion efficacy of itraconazole in preventing relapse of cryptococcal disease. Yet, in a recently completed two-step clinical trial of The purpose of our study was to assess the relative efficacy of itraconazole vs. fluconazole as maintenance therapy for AIDSprimary therapy for acute AIDS-associated cryptococcal meningitis in which itraconazole and fluconazole were compared as associated cryptococcal meningitis. At the time of initiation of the study, fluconazole at a dose of 200 mg/day was the treatconsolidation therapy following an initial 2 weeks of induction therapy with amphotericin B (with or without flucytosine), no ment of choice for preventing relapse among AIDS patients who had been successfully treated for acute cryptococcal dissignificant difference in clinical outcome was observed between the two treatment groups. However, a higher proportion ease [8] . Itraconazole was frequently used by AIDS clinicians in some areas of the world because of the drug's comparable of patients receiving fluconazole were culture-negative at the end of the 10 weeks of study [2] . activity to fluconazole in animal models of cryptococcal meningitis and in smaller phase II studies of cryptococcal disease
In the multivariate analysis of patients participating in the present study, previous treatment with fluconazole, itraconaamong HIV-infected patients [9 -12] . Because of the high success rate of fluconazole in preventing recurrence of cryptococzole, or amphotericin B followed by either azole agent was not associated with a higher risk of relapse of cryptococcal disease. cal disease (ú95% success) and the possibility that itraconazole might achieve a similar success rate and potentially less toxicHowever, the use of flucytosine during the first 2 weeks of primary therapy for acute cryptococcal meningitis was associity, this study was designed as an equivalence trial. The null hypothesis stated that fluconazole was at least 15% better at ated with an almost six-fold lower risk of relapse, regardless of the assigned maintenance treatment regimen. None of the preventing relapse of AIDS-associated cryptococcal meningitis than was itraconazole; if this hypothesis was rejected, the confluconazole recipients who received flucytosine as part of primary therapy relapsed, and only 2 of 13 with itraconazole clusion of our study would be that the two treatments were similar in efficacy. On the basis of the data from our study, failure had received flucytosine. The use of flucytosine in the primary therapy study was associated with a higher rate of the null hypothesis could not be rejected (P Å .735); therefore, at the doses used in this study, itraconazole is not as effective culture-negativity (51% without flucytosine vs. 60% with flucytosine) after 2 weeks of therapy [2] . Many possible factors as fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Indeed, the rate of culture-positive may be responsible for this observation, including a selection bias in favor of healthier patients (e.g., without neutropenia or relapse remained low (4%) among fluconazole recipients, consistent with the rates observed in previous studies. Thus, flucogastrointestinal disease) assigned to receive flucytosine concomitant with use of more potent antiretroviral therapy (not nazole should remain the therapy of choice in this setting.
Relapse of cryptococcal disease in this patient population controlled for in this study). However, the use of flucytosine during the first 2 weeks of primary therapy may lower total was not associated with any difference in overall survival. Indeed, none of the patients who relapsed died of cryptococcal body fungal burden of C. neoformans, resulting in both an improvement in culture-negative status achieved during acute disease. Nonetheless, relapsing cryptococcal meningitis is associated with significant morbidity. Each culture-positive relapse therapy and a decreased risk of relapse over time, regardless of whether itraconazole or fluconazole is used as maintenance in this study was symptomatic and commonly associated with recurrent headache and fever and, less commonly, with mental therapy. On the basis of previously conducted studies combined with status changes. Current recommendations for the treatment of both acute and recurrent cryptococcal meningitis suggest the data acquired in our study, fluconazole remains the treatment of choice as maintenance therapy to prevent relapse in AIDS use of amphotericin B for at least the initial 2 weeks of primary therapy [1] . Therefore, in addition to the signs and symptoms patients who have been successfully treated for acute cryptococcal meningitis. Although itraconazole, at the doses used in associated with relapse, patients must also contend with the / 9c61$$fe22 01-20-99 06:55:01 cidal UC: CID
